
ASCO GI 2022
CONTENTS
Online First
Oesophageal and Gastric Cancer
EMR versus ESD in oesophageal cancer
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
AK104 plus chemotherapy promising first-line option for gastric cancer

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The emerging role of AI in gastroesophageal cancer

DCF outperforms standard-of-care for locally advanced oesophageal cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
Anal and Colorectal Cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC

Dostarlimab may offer an alternative for dMMR rectal cancer
DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC
Key updates in colorectal cancer screening
Impact of COVID-19 on screening for colorectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Long-course chemoradiation versus short-course radiotherapy in rectal cancer
Analysis of metastasectomy in CRC reveals benefits and disparities
EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo
Hepatobiliary Cancer
Adjuvant S-1 therapy superior to observation in resected biliary tract cancer
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer
